Showing 3781-3790 of 5621 results for "".
- Humonix Biosciences Launches 3D Human Tissue Modelhttps://modernod.com/news/specialty-pharmaceutical-research-company-humonix-biosciences-launches-3d-human-tissue-model/2481864/Humonix Biosciences has developed a new 3D human tissue model called the retinal vascular dysfunction model. Humonix’s new model is a physiologically relevant 3D model of the blood-retinal barrier. This model expresses key physiological and biological characteristics, providing a platf
- Nanoscope Therapeutics Announces Presentations at Upcoming Conferenceshttps://modernod.com/news/nanoscope-therapeutics-announces-presentations-at-upcoming-conferences/2481862/Nanoscope Therapeutics, which is developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), is scheduled to participate in the 2023 Ophthalmology Futures Retina Forum and Euretina Innovation Spotlight at the 23rd Euretina Congress, each taking place
- Bausch + Lomb Completes Acquisition of Xiidrahttps://modernod.com/news/bausch-lomb-completes-acquisition-of-xiidra/2481861/Bausch + Lomb announced it has completed its acquisition of Xiidra (lifitegrast ophthalmic solution 5%), a non-steroid eye drop approved to treat the signs and symptoms of dry eye disease (DED) focusing on inflammation associated with dry eye. In June, Bausch + Lomb&
- Viatris Launches First National Direct to Consumer Campaign for Dry Eye Nasal Spray Tyrvayahttps://modernod.com/news/viatris-launches-first-national-direct-to-consumer-campaign-for-dry-eye-nasal-spray-tyrvaya/2481860/After nearly 2 years of educational programs to introduce Tyrvaya (varenicline solution) Nasal Spray to eye care professionals, the Viatris Eye Care Division announced it is rolling out a nationwide, multi-channel campaign. The new campaign, entitled “It’s Not Another Drop,&
- Harrow Health Changes Corporate Name to Harrow Inc.https://modernod.com/news/harrow-health-changes-corporate-name-to-harrow-inc/2481858/Harrow announced that effective today, it has changed its corporate name from “Harrow Health Inc.” to “Harrow Inc.” to align with the company’s current 5-year strategic plan, which includes an exclusive focus on eye care pharmaceuticals. “Gi
- LumiThera Receives NIH Grant to Support Dry AMD Trialhttps://modernod.com/news/lumithera-receives-nih-grant-to-support-dry-amd-trial/2481855/LumiThera announced it is a recipient of a small business innovative research (SBIR) phase 2 grant from the National Institute of Health (NIH) of up to $2.3 million in funding over 2 years. The NIH/NEI grant supports an open-label human clinical trial in intermediate dry
- Neurolens Introduces N3 VR-Based Measurement and Education Experiencehttps://modernod.com/news/neurolens-introduces-n3-vr-based-measurement-and-education-experience/2481854/Neurolens has introduced N3—a virtual reality experience designed to educate patients while measuring eye alignment. N3 provides an objective, accurate, and repeatable measurement of binocular alignment, which incorporates elements of heterophoria, fixation disparit
- Thea Pharma Announces the US Launch of Glaucoma Drug Iyuzehhttps://modernod.com/news/thea-pharma-announces-the-us-launch-of-glaucoma-drug-iyuzeh/2481850/Thea Pharma announced the launch and availability of Iyuzeh (latanoprost ophthalmic solution) 0.005% in the US market. Iyuzeh, which received FDA approval in December 2022, is the first and only preservative-free latanoprost for patients with primary open-angle glaucoma (
- PPG, Flō-Optics Announce Supplier Agreement for Digitally Applied Optical Coatingshttps://modernod.com/news/ppg-flo-optics-announce-supplier-agreement-for-digitally-applied-optical-coatings/2481849/PPG announced an exclusive supplier agreement with Flō-Optics, a developer of digital manufacturing technology for the ophthalmic industry, for the application of PPG HI-GARD scratch-resistant coatings using Flō’s proprietary digital printing technology. Financial terms of th
- Dopavision Completes Enrollment for MyopiaX-1 Trialhttps://modernod.com/news/dopavision-completes-enrollment-for-myopiax-1-trial/2481847/Dopavision, a clinical stage company developing solutions for myopia, announced the completion of enrollment in its MyopiaX-1 trial (NCT04967287). MyopiaX-1 is a randomized, active-controlled trial to evaluate the saf